Summary
AbbVie Inc. reported a decrease in net revenues for the third quarter and the first nine months of 2023 compared to the prior year, primarily due to the loss of exclusivity for Humira in the U.S. and continued biosimilar competition internationally. Despite the revenue decline, key growth drivers like Skyrizi and Rinvoq demonstrated significant year-over-year increases, signaling their growing contribution to the company's portfolio. The company also faced substantial non-cash charges, including a significant intangible asset impairment related to Imbruvica due to the Inflation Reduction Act, and changes in the fair value of contingent consideration liabilities, which impacted net earnings. AbbVie maintained a strong operating cash flow and continued its commitment to returning capital to shareholders through dividends and share repurchases, while also managing its debt levels. Looking ahead, AbbVie is focused on leveraging its diversified revenue base, advancing its robust pipeline of approximately 90 compounds, and executing new product launches. The company highlighted progress in its immunology, oncology, aesthetics, and neuroscience portfolios, with notable clinical trial results and regulatory submissions for key products. While the revenue headwinds from Humira are significant, the strong performance of newer assets and the strategic focus on pipeline development position AbbVie for future growth, though investors should remain mindful of the ongoing impact of patent expirations and competitive pressures.
Financial Highlights
56 data points| Revenue | $13.93B |
| Cost of Revenue | $6.49B |
| Gross Profit | $7.44B |
| SG&A Expenses | $3.37B |
| Operating Expenses | $11.65B |
| Operating Income | $2.28B |
| Interest Expense | $555.00M |
| Net Income | $1.78B |
| EPS (Basic) | $1.00 |
| EPS (Diluted) | $1.00 |
| Shares Outstanding (Basic) | 1.77B |
| Shares Outstanding (Diluted) | 1.77B |
Key Highlights
- 1Net revenues decreased by 6.0% (5.8% in constant currency) to $13.9 billion for the third quarter and 6.8% (6.0% in constant currency) to $40.0 billion for the nine months ended September 30, 2023, largely due to Humira's loss of exclusivity.
- 2Skyrizi and Rinvoq showed strong growth, with Skyrizi net revenues up 52.1% (51.9% constant currency) and Rinvoq up 59.8% (59.6% constant currency) for the third quarter.
- 3AbbVie recorded a significant pre-tax impairment charge of $2.1 billion on the definite-lived intangible asset related to Imbruvica in the U.S. due to selection for Medicare drug price negotiations under the Inflation Reduction Act.
- 4Diluted Earnings Per Share (EPS) was $1.00 for the third quarter and $2.26 for the nine months, significantly impacted by $5.1 billion in amortization of intangible assets, $3.3 billion for changes in fair value of contingent consideration liabilities, and $2.3 billion in intangible asset impairments for the nine-month period.
- 5Operating cash flow remained robust, generating $18.1 billion for the nine months ended September 30, 2023.
- 6The company continued its capital return program, with $7.9 billion in cash dividends paid and $1.6 billion in shares repurchased during the first nine months of 2023.
- 7AbbVie's pipeline remains a key focus, with approximately 90 compounds in development, including over 50 in mid- and late-stage development across immunology, oncology, aesthetics, neuroscience, and eye care.